[(3S)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate | 760163-21-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 奎宁环
• 英文名称: [(3S)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate
• CAS: 760163-21-1
• 化学式: C26H30NO4S2+
• 分子量: 484.7
• InChiKey: ASMXXROZKSBQIH-QHMKHHNBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  33
• 可旋转键数：
  10
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  112
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Medicament Combinations for the Treatment of Respiratory Diseases
  申请人：Konetzki Ingo

  公开号：US20070203125A1

  公开（公告）日：2007-08-30

  The present invention relates to new medicament combinations which contain in addition to one or more, preferably one compound of general formula 1 wherein A, B, R 1 , X, n and m may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

  本发明涉及新的药物组合物，除了一个或多个，最好是1号通用公式中的一个化合物外，其中A、B、R1、X、n和m的含义如权利要求和说明书中所给，至少还包含另一种活性物质2，以及它们的制备方法和作为药物组合物的用途。
• PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES
  申请人：Konetzki Ingo

  公开号：US20080051392A1

  公开（公告）日：2008-02-28

  The present invention relates to new pharmaceutical combinations which contain in addition to one or more, preferably one compound of general formula 1 wherein the groups R 1 , R 2 and R 3 may have the meanings given in the claims and specification, at least one further active substance 2, processes for preparing them and their use as medicaments.

  本发明涉及包含除了一个或多个一般式1的化合物之外，至少一个进一步的活性物质2的新药物组合，其中R1、R2和R3基团可能具有权利要求和说明书中给定的含义，以及其制备方法和作为药物的用途。
• Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient
  申请人：KONETZKI Ingo

  公开号：US20070037781A1

  公开（公告）日：2007-02-15

  Disclosed are medicament combinations which contain in addition to one or more, preferably one, compound of general formula 1 wherein the groups X, R a , R b , R 1 , R 1′ , R 2 , R 2′ , R 2″ , R 2′″ , V and n may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

  公开了药物组合物，除了一个或多个，最好是1个，通用公式1中的化合物之外，还包括至少一个其他活性物质2，其中X，Ra，Rb，R1，R1′，R2，R2′，R2″，R2′″，V和n的含义如权利要求和说明书中所述，以及它们的制备方法和作为药物组合物用途。
• DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES
  申请人：Konetzki Ingo

  公开号：US20090324510A1

  公开（公告）日：2009-12-31

  The present invention relates to novel drug combinations which, besides one or more, preferably on compound of the general formula (1), wherein remainder n, A, R1, R2, and R3 can have the meanings given in the claims and in the description comprise at least one further active ingredient 2 and method for the production thereof and the use thereof as drugs.

  本发明涉及除了一个或多个，更优选的是一个具有通用公式（1）的化合物，其中n、A、R1、R2和R3的含义如权利要求和描述中所述，至少还包含另一种活性成分2及其生产方法和作为药物的使用。
• NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
  申请人：ALMIRALL, S.A.

  公开号：US20150246026A1

  公开（公告）日：2015-09-03

  A compound according to formula (I) wherein z© is a phenyl ring, a C 4 to C 9 heteroaromatic compound containing one or more heteroatoms, or a naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl or biphenyl group; R 1 , R 2 and R 3 each independently represent a hydrogen or halogen atom, or a hydroxy group, or a phenyl, —OR 4 , —SR 4 , —NR 4 R 5 , —NHCOR 4 , —CONR 4 R 5 , —CN, —NO 2 , —COOR 4 or —CF 3 group, or a straight or branched lower alkyl group which may optionally be substituted, for example, with a hydroxy or alcoxy group, wherein R 4 and R 5 each independently represent a hydrogen atom, straight or branched lower alkyl group, or together form an alicyclic ring; or R 1 and R 2 together form an aromatic, alicyclic or heterocyclic ring; n is an integer from 0 to 4; A represents a —CH 2 —, —CH═CR 6 , —CR 6 ═CH—, —CR 6 12 2 —, —CO—, —O—, —S—, —S(O)—, SO 2 or NR 6 — group, wherein R 6 and R 2 each independently represent a hydrogen atom, straight or branched lower alkyl group, or R 6 and 12 2 together form an alicyclic ring; m is an integer from 0 to 8; provided that when m=0, A is not —CH 2 —; p is an integer from 1 to 2 and the substitution in the azoniabicyclic ring may be in the 2,3 or 4 position including all possible configurations of the asymmetric carbons; B represents a group of formula (i) or (ii), wherein R 10 represents a hydrogen atom, a hydroxy or methyl group; and R 8 and R 9 each independently represents formulae (a), (b), (c), (d) and wherein R 11 represents a hydrogen or halogen atom, or a straight or branched lower alkyl group and Q represents a single bond, —CH 2 —, —CH 2 —CH 2 , —O—, —O—CH 2 —, —S—, —S—CH 2 — or —CH═CH—, and when (i) or (ii) contain a chiral centre they may represent either configuration; X represents a pharmaceutically acceptable anion of a mono or polyvalent acid, which shows high affinity for muscarinic M 3 receptors (Hm3).

  根据式(I)的化合物，其中z©是苯环，含有一个或多个杂原子的C4至C9杂芳环化合物，或者是萘基、5,6,7,8-四氢萘基或联苯基；R1、R2和R3分别独立表示氢原子或卤素原子，或羟基，或苯基，—OR4，—SR4，—NR4R5，—NHCOR4，—CONR4R5，—CN，—NO2，—COOR4或—CF3基团，或直链或支链低碳烷基基团，该基团可能被羟基或烷氧基取代，其中R4和R5分别独立表示氢原子，直链或支链低碳烷基基团，或者共同形成脂环；或者R1和R2共同形成芳香环、脂环或杂环；n是从0到4的整数；A表示—CH2—，—CH═CR6，—CR6═CH—，—CR6122—，—CO—，—O—，—S—，—S(O)—，SO2或NR6—基团，其中R6和R2分别独立表示氢原子，直链或支链低碳烷基基团，或者R6和122共同形成脂环；m是从0到8的整数；但当m=0时，A不是— —；p是从1到2的整数，而在azoniabicyclic环中的取代基可以在2,3或4位置，包括对不对称碳的所有可能构型；B表示式(i)或(ii)的基团，其中R10表示氢原子，羟基或甲基基团；而R8和R9分别表示式(a)，(b)，(c)，(d)，其中R11表示氢原子或卤素原子，或者直链或支链低碳烷基基团，Q表示单键，— —，— — ，—O—，—O— —，—S—，—S— —或—CH═CH—，当(i)或(ii)含有手性中心时，它们可以表示任一构型；X表示单价或多价酸的药用可接受阴离子，对M3胆碱能受体（Hm3）具有高亲和力。